Tools chosen: polymarket_direct polymarket_related kalshi_related claude_news gdelt_news wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a two-stage question: (1) does Oura IPO at all before Dec 31, 2026, and (2) conditional on IPO, does the first-day closing market cap land in the $7.5B–$10B bracket. Oura's last known private round valued it around $11B (late 2025), so the bracket sits below the private mark, making it important to nail the latest valuation, filing status, and comparable IPO first-day pops. The Polymarket price on this and sibling bracket markets is the primary anchor.

# Current state Oura confidentially filed for a US IPO on 2026-05-21 (Bloomberg/CNBC), with Goldman Sachs and JPMorgan underwriting; no share count, price range, or listing date has been disclosed yet. The market resolves on Oura's actual first-day closing market cap, not on rumors or filing status — a confidential filing is a precursor, not proof of a 2026 IPO or of pricing in the $7.5B–$10B band. Last known private valuation ($11B, Oct 2025 Series E) sits above the target range's upper bound. # Timeline of key events - 2024-12: Series D round, $200M raised at $5.2B valuation (confirmed, claude_news). - 2025-09-22: Reports Oura raising ~$875M Series E at ~$11B valuation (reported, TechCrunch). - 2025-10-14: Oura confirms $900M+ Series E closed, valuation $11B, led by Fidelity, with ICONIQ, Whale Rock, Atreides (confirmed, CNBC). - 2025 (year): Oura reports ~$1B revenue for 2025, 5.5M rings sold, guidance of >$1.5B 2026 sales (confirmed/company-reported). - 2025-11: CEO Tom Hale projects Oura could approach $2B in 2026 sales (reported executive projection, Sacra). - 2026-03: Reports Oura interviewing banks for a possible IPO "as soon as this year" (reported, The Information). - 2026-05-21: Oura confidentially files for US IPO; underwriters Goldman Sachs & JPMorgan (confirmed, Bloomberg/CNBC). - 2026-05-27/28: Oura launches Ring 5 (smallest smart ring, $399) alongside IPO-track publicity; company states ~5M paid members, 4x revenue growth over two years (confirmed, multiple outlets). - 2026-06 to 2026-07: Continued press coverage of wearables IPO landscape; no confirmed pricing, roadshow, or listing date reported as of latest data. # Event Will Oura's market cap fall between $7.5B and $10B at close of its first IPO trading day (resolves "No IPO before January 2027" if no IPO occurs by 2026-12-31)? # Outcomes to forecast Yes / No (bucket: closing market cap in [$7.5B, $10B]) # Kalshi market anchor No direct Kalshi price returned for this ticker in raw research (kalshi_direct data absent from tool output). Related Kalshi IPO-race markets (Ramp/Brex, OpenAI/Anthropic) show no Oura-specific pricing. **Primary anchor is Polymarket** for this specific bracket: current YES price 14.5%, up +4% (7d), +1% (30d), range 7.5%–48.5% over 89 days, volume ~$52.7K (thin). # Sub-question answers 1. **IPO filing/timeline** — Confidentially filed 2026-05-21 (Bloomberg/CNBC); Goldman Sachs/JPMorgan underwriting; no disclosed price range, share count, or firm listing date as of latest data. 2. **Recent valuation/capital raised** — Series E (Oct 2025): $900M+ raised at $11B valuation, led by Fidelity; Series D (Dec 2024): $200M at $5.2B. Total lifetime capital raised: $1.5B since 2013 (claude_news). 3. **Polymarket bracket pricing** — This specific $7.5B–$10B bracket trades at 14.5%; no full cross-bracket table was retrieved, so implied "no IPO before 2027" probability is unknown from raw data. 4. **Base rate for rumored IPO completing in ~13-month window** — Not directly answered by research; code_execution model assumes IPO probability by year-end 2026 of 15%–40% (midpoint ~25%) as a sensitivity input, not an empirical base rate. 5. **Comparable hardware/health-tech IPO pricing vs last private round** — Not addressed in raw research; no specific comp data retrieved. 6. **Revenue run-rate/comps multiple** — 2025 revenue ~$1B, 2026 guidance $1.5B–$2B (CEO projection); 4x revenue growth over 2 years; no explicit public-comp multiple analysis was returned. # Key facts (high-confidence, factual) 1. [Bloomberg/CNBC] Confidential S-1 filing 2026-05-21; underwriters Goldman Sachs, JPMorgan. 2. [CNBC/TechCrunch] Oct 2025 Series E: $11B valuation, $900M+ raised. 3. [claude_news] Dec 2024 Series D: $5.2B valuation, $200M raised. 4. [claude_news] 2025 revenue ~$1B; 2026 guidance $1.5B, CEO stretch target ~$2B. 5. [Wikipedia] 5.5M rings sold by Sept 2025; company founded 2013, Finland-based, HQ San Francisco. 6. [Polymarket] This bracket ($7.5B-$10B) priced at 14.5% YES, thin volume (~$52.7K), high historical volatility (7.5%-48.5%). # Cross-market signals - Kalshi related: No Oura-specific market found; adjacent IPO-race markets show active Kalshi pricing culture for tech IPOs but no transferable signal. - Polymarket: Target bracket at 14.5%; no other bracket prices retrieved for cross-check/de-vig. - Sportsbook implied: N/A. # Analyst opinions and speculation - claude_news synthesis: last private valuation ($11B) exceeds range upper bound ($10B); given 4x revenue growth and investor enthusiasm, a $7.5B–$10B close would represent a valuation **discount** to last round — plausible under cooler market conditions or conservative pricing, but not the base case. - code_execution modeling: using lognormal pricing centered at last private valuation ($11B, sigma 0.35-0.50) and IPO-by-2027 probability 15-40%, conditional probability of landing in band ≈20-32%, unconditional ≈2.5%-12.7% (central estimate ~6%). # Directional lean per outcome - **Yes ($7.5B-$10B)**: Supported by common IPO pricing at discount to last private round (down-round-adjusted listings common in 2022-2024 vintage), and range is directly below last valuation. Opposed by strong revenue growth (4x in 2 years), investor enthusiasm (Fidelity-led raise), and rising 2026 guidance — all pushing toward pricing at or above $11B, not below $10B. - **No (including no-IPO and outside range)**: Favored by (a) meaningful chance IPO slips past 2026 given only confidential filing stage with no roadshow/date set, and (b) if IPO does occur, momentum/growth narrative and typical "pop" dynamics favor pricing at/above last private mark (~$11B+), landing outside the $7.5-10B band on the high side. # Gaps / unknowns - No confirmed Kalshi YES price captured in this research pull despite being labeled the primary anchor — treat Polymarket (14.5%) as best available cross-market reference. - No full Polymarket bracket table (can't verify total probability mass or de-vig). - No firm IPO date, pricing range, or share count disclosed. - No comparable-IPO discount/premium data (sub-question 5 unanswered). - No explicit base rate for confidential-filing-to-completed-IPO conversion within 13 months. # Calibration anchors - Polymarket current YES price for this exact bracket: 14.5% (anchor). - Model-based central estimate (code_execution): ~6% (range 2.5%-12.7%) under base-case assumptions. - Last private valuation ($11B) sits above this bracket's ceiling, implying downside pricing needed for Yes.

1. Both forecasters land at 10-13%, notably below the Polymarket anchor of 14.5%, but neither offers strong evidence for discounting the anchor beyond "thin volume" — thin volume with high volatility (7.5%-48.5% range) could just as easily argue for wider uncertainty around 14.5% rather than a directional pull downward. 2. Forecast 1 asserts a "~50-60% chance of a 2026 listing" with no empirical support; the brief explicitly states "no explicit base rate for confidential-filing-to-completed-IPO conversion within 13 months" was found, and given Oura is still at the confidential-filing stage with no roadshow/date/range as of the latest data (~7 months before close), a base rate closer to 30-40% seems equally defensible — this key parameter is unjustified and undisclosed as a sensitivity. 3. Neither forecast meaningfully engages sub-question 5 (comparable hardware/health-tech IPO pricing vs. last private round), despite the brief flagging that "down-round-adjusted listings common in 2022-2024 vintage" is a real precedent supporting the Yes case; both dismiss this as "not the base case" without weighing how common post-2022 IPO discounts to last private mark actually were. 4. Both forecasts treat the conditional-on-IPO distribution as concentrated near/above $11B with only ~20-25% chance in the $7.5-10B band, but given the wide range of plausible sigma (0.35-0.50 lognormal per code_execution) and revenue guidance itself spanning $1.5B-$2B (a wide multiple range), the conditional probability could reasonably be argued higher (30%+) — this compresses the tail without justification. 5. Neither forecast addresses potential upside/downside asymmetry from the Ring 5 launch and "4x revenue growth over two years" publicity co-timed with the IPO filing (2026-05-27/28), which could be read as pre-IPO narrative-building to justify pricing at or above $11B, strengthening the No case slightly more than either forecast's conditional estimate reflects. 6. There's an internal inconsistency between the two forecasts' implied decomposition: Forecast 1 explicitly multiplies ~50-60% (listing) × ~20-25% (bucket conditional) ≈ 12-14%, while Forecast 2 does not decompose at all and simply anchors to the model's unconditional 2.5-12.7% range — this makes it hard to see whether their disagreement stems from differing listing-probability assumptions or differing bucket-conditional assumptions, an important diagnostic gap.

12% (49% confidence)

Yes: 12% No: 88%

Yes requires two things: (a) Oura actually lists before 2027, and (b) the first-day close lands in the $7.5B-$10B band, below its $11B Oct-2025 private mark. As of the latest data Oura is only at the confidential-filing stage with no roadshow, price range, or date — I put a 2026 listing at roughly 40-55%, lower than Forecast 1's assumption per the critique. Conditional on listing, strong momentum ($1B 2025 revenue, $1.5-2B 2026 guidance, Ring 5 launch as pre-IPO narrative-building, Fidelity-led round) makes pricing at/above $11B the base case, though post-2022 discount-to-last-round listings are common enough to keep the band's conditional probability around 25-30% rather than the ~20% both forecasters used. Multiplying gives ~11-14%, essentially at the thin but only available Polymarket anchor of 14.5%; the wide historical range (7.5%-48.5%) argues for uncertainty rather than a strong directional discount, so I settle slightly below the anchor at 12%.

Total pipeline time: 238.1s